

ASX ANNOUNCEMENT

DATE: 21 May 2020

VIRTUS HEALTH LIMITED (ASX: VRT)

UBS EMERGING COMPANY CONFERENCE PRESENTATION

Virtus Health Limited (ASX "VRT", "Virtus") is presenting at the UBS Emerging Company Conference today and is pleased to disclose the management presentation (attached to this announcement).

Authorised by the Board of Directors of Virtus Health.

ENDS

Further information:

Kate Munnings

CEO

Virtus Health

+61 (0)2 9425 1722

Angela Read

PR and Media Specialist

Virtus Health

+61 (0)428 448 719

angela.read@virtushealth.com.au

About Virtus Health Limited

Virtus Health Limited (ASX:VRT) brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care and related specialised diagnostic and day hospital services. We have developed one of the most successful medical collaborations in the world. With 127 of the world's leading fertility specialists supported by over 1300 professional staff, we are the largest network and provider of fertility services in Australia and Ireland, with a growing international presence in the UK, Denmark and Singapore.

UBS EMERGING COMPANY CONFERENCE

Leading through lockdown

21 May 2020

PIVOTING, PLANNING AND
PERSEVERING THROUGH COVID-19

A global leader in Assisted Reproductive Services



119

Fertility Specialists



247

Scientists



1,005

Nurses,
counsellors,
patient support &
operational staff



43

Fertility clinics



56

Laboratories



7

Day Hospitals



7

Diagnostics labs



5

Countries



>37,000

Fertility patients annually



>32,000

Hospital patients annually



>1 million

Diagnostics tests annually

60 days in office

Kate Munnings, Group CEO

A high performing unit.

- Strong market fundamentals
- Operational excellence across multiple geographies & regulatory environments
- Clear purpose and values
- Research and innovation
- Optimised cost reduction strategies
- Provider of scale with the largest market share in Australia, Ireland and Denmark
- Net Promoter Score 57+

- Commitment to quality and scientific rigor
- Strong government relations
- Access to significant set of genotype and phenotype data
- Greater flexibility of service location (more home/platform based services)

Harnessing talent.

- The world's best embryologists
- The highest calibre of specialists
- Strong operational talent
- Collaboration among local units

Operational status

SINGAPORE:

- Operations continued, slowdown of operations due to second wave
- Restarted 18 May 2020
- May activity impacted

EUROPE:

- Denmark and Ireland have resumed IVF operations
- UK preparing to reopen

AUSTRALIA:

Fertility.


- Fertility clinics resumed IVF from 27 April
- Increased infection control to protect patients and staff
- Leveraging telehealth


Day hospitals.

- Resumed ARS and non-IVF elective surgery, increased safety protocols
- Ready to assist health response to COVID-19, but not a party to State Government viability contracts

Diagnostics.

- Increased staffing as ARS operations return to normal levels and demand for non-IVF diagnostic testing rises.






Financial position

NO SHORT-TERM CAPITAL RAISING

Banking partners agree to relevant normalisations to covenant calculations for reporting periods up to 31 December 2020

Strength of balance sheet and cash flows

As at 30 April 2020



\$25M

Cash balances

\$84.8M


Available debt
facilities

\$173M

Borrowings

\$5.2M


Guarantees




Looking forward

INVESTING IN INNOVATION & PERFORMANCE

A plan for growing our market leadership post-COVID.





Pioneering AI in IVF

Published 15 May 2020 across Fairfax publications: The Sydney Morning Herald, The Age and The Brisbane Times

EXCLUSIVE NATIONAL IVF

Huge trial under way for 'very promising' AI tool to boost IVF success

“ Australian fertility experts are now testing the technique , which uses artificial intelligence to improve the odds of a successful pregnancy, in the largest trial of its kind in the world.

As part of the international study, led by national fertility provider Virtus Health, 1,000 patients will be recruited at five IVF clinics across Australia, alongside sites in Ireland and Denmark.

What the AI tool can do is analyse all the embryos. The embryo with the highest score can then be selected for transfer by the embryologist with the aim of accelerating the chance to a successful pregnancy.

”



Future roadmap



Investing in people and culture
Leaders in innovation and translational research
Optimising data and technology

DURING COVID

Opex management
Patient engagement
Process harmonisation

POST COVID

Invest in capability
Business development
Health partnerships

POSITION FOR GROWTH

One Lab and One Clinic
AI and technology
Growth opportunities